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TDITORIAL COMMENT
eart Transplantation:
he Increasing Challenges of
vidence-Based Decision-Making*
ario C. Deng, MD, FACC, FESC
ew York, New York
he benefit of heart transplantation has never been tested in
randomized clinical trial because heart transplantation has
lways been considered a breakthrough therapy according to
riteria of evidence-based medicine, namely following early
linical results from Stanford University (1). Although heart
ransplantation has become the accepted gold standard for
he treatment of carefully selected patients (2) with stage D
eart failure (3), patient selection criteria for and outcomes
fter heart transplantation have to constantly be reevaluated
n the context of contemporary organ-saving therapies for
dvanced heart failure. The Comparative Outcomes &
linical Profiles in Transplantation study in Germany
uggested that those patients who, according to the use of a
alidated heart failure survival score (HFSS), would have
he highest risk of dying from their heart failure would
See pages 787 and 794
erive the greatest survival benefit during the first year after
eart transplantation (4). Similar results were obtained in
he U.S. (5). Based on these results, the hypothesis has been
aised that stable outpatients on the United Network for
rgan Sharing (UNOS) status 2 heart transplantation
aiting list may not derive a clear benefit from transplan-
ation. Although this hypothesis could theoretically be
ested in a randomized clinical trial (6), this study would be
ifficult to design and conduct (7). Alternatively, observa-
ional data gathered by a sophisticated database mechanism
ay provide clues, albeit with less strength.
To provide this type of information, these observational
ata require stratification of heart failure risk at the time of
isting and transplantation. To be translated into clinical
ractice, these risk scores have to be incorporated into the
aily decision-making algorithm of experienced heart fail-
re/transplant centers. Currently, there are two scores avail-
ble, the HFSS (8), which is based on the peak oxygen
onsumption measurement that was introduced by Mancini
t al. (9) into heart failure risk stratification, and the
erman Transplantation Society Score (10).
In this context, the two studies in this issue of the Journal
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From Columbia University College of Physicians and Surgeons, New Yorkeresbyterian Hospital, New York, New York.11,12) shed new light. The group from Vanderbilt Uni-
ersity (11) addresses the changing role of a validated heart
ailure risk score, indicating that in the more recent con-
emporary era it loses some of its predictive potential. This
s a very interesting clinical study investigating the relation-
hip between pretransplant survival, peak exercise oxygen
onsumption, and the HFSS in two different eras and
omparing the survival outcomes of these two cohorts to the
espective survival outcomes after heart transplantation. The
uthors hypothesize that outcomes with conventional heart
ailure therapy have improved over time and that, therefore,
he risk prediction by Vo2 and HFSS, as well as the survival
enefit from cardiac transplantation, is less clear in the more
ecent era. The design chosen to examine this hypothesis
as a retrospective analysis at Vanderbilt University of 320
atients who were listed for cardiac transplantation and
ollowed medically between 1993 and 1997, 187 patients
ho were listed for cardiac transplantation and followed
edically between 1999 and 2001, and 184 patients who
ere undergoing heart transplantation between 1993 and
001. The authors found that in the medically treated
roup, survival in the past era was 78% at one year and 67%
t two years as compared with 88% and 79% in the current
ra, respectively. One-year post transplantation survival was
8%. The authors conclude that patients with a low-risk
FSS and VO2 between 10 and 14 ml/kg/min should no
onger be listed for cardiac transplantation because the
ne-year post-transplantation survival rate was similar.
The group from Harvard University (12) addresses—in a
omplementary way in discussing the above outlined prob-
em—the integration of risk predictors in a practical clinical
lgorithm and its impact on outcomes. This is a very
nteresting clinical study investigating the impact of delayed
isting for cardiac transplantation on survival. The authors
ypothesize that because outcomes with conventional heart
ailure therapy have improved over time, delayed versus
mmediate listing for heart transplantation in stable patients
ould not reduce overall survival because the survival benefit
rom cardiac transplantation in stable patients is less clear in
he more recent era. The design chosen to examine this
ypothesis was a retrospective analysis at Harvard Medical
chool of transplant committee decisions classifying pa-
ients after initial evaluation with respect to cardiac trans-
lantation listing into “eligible,” “potentially eligible,” “in-
ligible,” and “deferred” and their survival outcomes before
nd after heart transplantation. Within the group consid-
red “eligible,” the subgroups listed “early” (within 10 days
fter the committee decision) and “not early” were com-
ared. The authors found that of a total of 214 patients
valuated for transplant, 44% were deemed eligible, 25%
otentially eligible, 19% ineligible, and 12% were deferred.
f the eligible patients, 37% of patients were listed within
0 days, and a total of 71% were listed at any time.
hree-year survival rates in eligible patients were similar inligible patients not listed early and in patients listed early.
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Editorial Comment March 3, 2004:803–5neligible and potentially eligible patients had higher three-
ear mortality rates than eligible patients with or without
ransplantation. The authors conclude that using currently
ccepted guidelines, many patients referred for transplant
valuation and considered eligible who were not listed
nitially did well long term and therefore may not require
arly listing and that patients with relative contraindications
ad worse outcomes with or without transplantation.
Critically reflecting on both studies, the main method-
logical problem in the Butler et al. (11) in comparing
utcomes between the two medically treated groups as well
s between the medically treated groups and the heart
ransplant group is the assumption that each of the groups
as a similar clinical and heart failure risk profile. This
ssumption is necessary to allow for the conclusion that
ifferences in survival outcomes are due to differences in the
ffectiveness of the interventions (medical heart failure
herapy in two eras, and heart transplantation, respectively).
s this assumption valid in the Butler et al. (11) study? The
FSS score distribution between the medically treated
atients of the past era and the present era was not the same.
here was a lower fraction of high- and medium-risk
atients and a higher fraction of low-risk patients in the
urrent era. Thus, differences in survival could be poten-
ially, at least partially, due to differences in baseline
haracteristics. The clinical profile, VO2, and HFSS risk
core of patients undergoing heart transplantation was not
escribed and statistically compared with either or both
retransplant groups.
On a similar notion in the Lewis et al. paper (12), the
ain methodological problem in this retrospective observa-
ional study in testing the effect of early versus delayed
ransplant listing on outcomes between the different groups
hat were “eligible” and listed as “early” or “not early” is the
ssumption that the groups have a comparable clinical
rofile regarding their risk of death from heart failure
ithout transplantation and that, indeed, the intervention
early versus delayed intention to treat by cardiac transplan-
ation” is being tested. This assumption is necessary to allow
or the conclusion that differences in survival outcomes are
ue to differences in the timing of the intervention (early vs.
elayed listing for heart transplantation, respectively). How-
ver, if this assumption is violated and the clinical profile
nd associated risk of dying from heart failure without
ransplantation is different between the two groups, then
ifferences in outcome may have to be attributed to these
ifferences as opposed to the timing of transplant listing.
ndeed, the patients listed early had a lower peak oxygen
onsumption (11.4 vs. 13.3 ml/kg/min, p 0.02). A similar
ethodological problem in this retrospective observational
tudy exists with the opposite assumption that the clinical
rofile and thus the risk of dying from heart failure without
ransplantation between the groups considered “eligible,”
potentially eligible,” “ineligible,” and “deferred” is different.
his assumption is necessary to allow for the conclusion that
ifferences in survival outcomes are due to differences in thelinical profile at the time of the initial evaluation. However,
t is conceivable that by making a committee decision the
ubsequent management would not continue to be the same
or the different groups and, thus, have an impact on
utcomes themselves. Indeed, not all ineligible patients who
ere not listed for transplantation were followed by the
eart Failure/Transplant group at Harvard University.
The second methodological challenge in this kind of
nalysis is the form of transition from the pretransplant
roup into the post-transplant group over the time course of
he respective study periods. For example, if a UNOS rule
avors elective transplantation as UNOS status 2 patients
nd thereby leads to continuous removal of a large fraction
f stable patients from the waiting list, there may be a
ime-dependent increase in the severity of heart failure in
he remaining waiting list population, increasing their risk
f dying. At the same time, this would lead to a favorable
ost-transplantation outcome because of the high fraction
f stable patients being transplanted. If, however, the
NOS rule would favor the transplantation of critically ill
nd/or unstable patients, the opposite trend would ensue.
hus, this transition requires methods for time-dependent
odeling of risks in the respective groups.
Bearing these limitations in mind, one would agree with
he conclusion of the Butler et al. (11) and Lewis et al. (12)
tudies that patients at low (not high or intermediate) risk of
ying from heart failure may not require immediate listing
nd possibly should not undergo transplantation in the
urrent era. This discussion has been open for some years
4,6).
In summary, with contemporary therapy, less benefit of
eart transplantation in stable patients is seen. Although heart
ransplantation may not be in a crisis altogether (13), heart
ailure risk scores and heart transplantation survival and quality
f life benefit need to be continuously reevaluated in the
ontext of constantly changing competing therapies for ad-
anced heart failure that not only include advances in medical,
efibrillator and pacemaker therapy but also chronic mechan-
cal circulatory support device therapy (14–16). The major
ontinuous challenge is to integrate this information into our
aily encounter with and management algorithms for our
dvanced heart failure patients (17).
eprint requests and correspondence: Dr. Mario C. Deng,
olumbia University College of Physicians and Surgeons, New
ork Presbyterian Hospital, Milstein Hospital Building Room
-407, 177 Fort Washington Avenue, New York, New York
0032. E-mail: md785@columbia.edu.
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